Combining Antibody Therapy and Interferon for Liver Cancer Treatment
Author Information
Author(s): Sasaki Shigeru, Ishida Tadao, Toyota Minoru, Ota Akinobu, Suzuki Hiromu, Takaoka Akinori, Yasui Hiroshi, Yamamoto Hiroyuki, Takagi Hideyasu, Maeda Masahiro, Seito Tsutomu, Tsujisaki Masayuki, Shinomura Yasuhisa, Imai Kohzoh
Primary Institution: Sapporo Medical University, Sapporo, Japan
Hypothesis
Can the combination of anti-FGFR1 monoclonal antibody and interferon-α/β effectively treat hepatocellular carcinoma (HCC)?
Conclusion
The combined use of an anti-FGFR1 antibody and interferon-α/β is a promising approach to the treatment of HCC.
Supporting Evidence
- Interferon-α/β was found to induce FGFR1 expression in human HCC cell lines.
- The combination treatment showed significant antitumor effects in vitro.
- In a mouse model, the combination treatment led to tumor regression in some cases.
Takeaway
This study found that a special treatment using a combination of a specific antibody and a medicine called interferon can help fight liver cancer cells.
Methodology
The study used Western blot, flow cytometry, and immunocytochemical analyses to investigate FGFR1 expression and tested the treatment in a murine xenograft model.
Potential Biases
Potential bias due to the involvement of authors from a company that produces the antibodies used in the study.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
The study involved human hepatic cancer cell lines and SCID mice.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website